Welcome to Awesome Blog Design perfect blog
Business

LianBio announces clearance to initiate the Phase 3 PROOF trial of Infigratinib in patients with locally advanced or metastatic unresectable cholangiocarcinoma with FGFR2 gene fusions in China

Michelle Dryden Comments Off on LianBio announces clearance to initiate the Phase 3 PROOF trial of Infigratinib in patients with locally advanced or metastatic unresectable cholangiocarcinoma with FGFR2 gene fusions in China

SHANGHAI & PRINCETON, N.J.–(BUSINESS WIRE)–LianBio, a biotechnology company focused on bringing paradigm-shifting medicines to patients in China and major Asian markets, today announced that it has received clearance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration

Business, Healthcare

Catalent, Inc. reports first quarter fiscal 2021 results

 Q1’21 net revenue of $845.7 million increased 27% as-reported, or 26% in constant currency, compared to Q1’20. On an organic basis, constant currency net revenue in Q1’21 grew 20% compared to Q1’20.  Q1’21 Adjusted EBITDA of $174.4 million increased 37% as-reported, or